Vascular Dementia

Chapter 444 | Part 13: Neurologic Disorders

KEY CLINICAL POINTS

• Vascular dementia (VCID) encompasses cerebrovascular disease's impact on cognitive decline, including large strokes, small-vessel disease, and mixed etiologies.
• Global disparities in vascular dementia risk exist due to racial/ethnic differences in intracranial vs. extracranial disease prevalence.
• MRI markers like lacunar infarcts, microbleeds, and white matter hyperintensities are critical for diagnosis and monitoring.
• SPRINT-MIND trial showed SBP <120 mmHg reduced dementia risk by 15% (HR 0.85) compared to 140 mmHg.
• Mixed vascular-neurodegenerative dementias are more common than single-etiology dementias.

1. DEFINITION & OVERVIEW

Vascular dementia refers to cognitive impairment caused by cerebrovascular disease, including large strokes, small-vessel disease, and mixed etiologies. VCID (vascular contributions to cognitive impairment and dementia) reflects cumulative effects of cerebrovascular pathology on age-related cognitive decline.

MRI Markers of Cerebral Small-Vessel Disease

MRI Finding	Location	Associated Pathology
Lacunar infarct	Deep white matter/thalamus	Arteriolosclerosis
Cerebral microbleeds	Pons (arteriolosclerosis) / Lobar (amyloid angiopathy)	Small-vessel disease
White matter hyperintensities	Periventricular/subcortical	Vascular injury, demyelination

1.1 Subtypes of Cerebrovascular Disease

Large cerebral strokes (ischemic/ hemorrhagic), cerebral small-vessel disease (arteriolosclerosis, cerebral amyloid angiopathy), and multifactorial/mixed dementias. Small-vessel disease accounts for ~20% of cognitive decline in >30% of postmortem brains.

1.2 Diagnostic Criteria

Clinical diagnosis based on history of stroke or vascular risk factors, supported by MRI findings (e.g., lacunar infarcts, white matter hyperintensities). Distinguishes from Alzheimer’s disease through pattern of cognitive impairment and neuroimaging.

2. EPIDEMIOLOGY

Vascular dementia is second most common dementia cause after Alzheimer’s. Global incidence rates declined from 3.6/100 person-years (1978–1980) to 2.0/100 person-years (2008–2010), correlating with improved hypertension control and stroke prevention. Risk factors include age, hypertension, diabetes, and racial/ethnic disparities in vascular disease patterns.

2.1 Incidence & Prevalence

Population-based Framingham Study: 3.6/100 person-years (1978–1980) to 2.0/100 person-years (2008–2010). 50% of stroke survivors show cognitive impairment, increasing with follow-up duration.

2.2 Risk Factors

Hypertension, diabetes, hyperlipidemia, smoking, and vascular risk factors. Racial/ethnic disparities: higher intracranial atherosclerosis in Asians/Hispanics/Blacks vs. extracranial disease in Whites.

3. ETIOLOGY & PATHOPHYSIOLOGY

Cerebrovascular disease mechanisms include large vessel strokes, small-vessel arteriolosclerosis, and cerebral amyloid angiopathy. Pathogenesis involves vascular injury, hypoperfusion, and neuroinflammation, with cumulative effects on white matter integrity.

3.1 Small-Vessel Disease Pathologies

Arteriolosclerosis (thickened arterioles from plasma protein infiltration) and cerebral amyloid angiopathy ( β -amyloid deposition in small vessels). Arteriolosclerosis risk factors: age, hypertension, diabetes. Amyloid angiopathy risk: advancing age.

3.2 Poststroke Cognitive Decline

Mechanisms include ongoing vascular injury, loss of cognitive reserve, and neuroinflammation. SPRINT-MIND trial showed SBP <120 mmHg reduced dementia risk by 15% (HR 0.85).

4. CLINICAL FEATURES

Cognitive impairment from focal brain injury (e.g., executive dysfunction, visuospatial deficits) or diffuse white matter damage. Common presentations include stepwise decline, fluctuating cognition, and gait disturbances. MRI shows lacunar infarcts, microbleeds, or white matter hyperintensities.

4.1 Cognitive Profiles

Executive dysfunction, slowed processing, and visuospatial deficits. Memory impairment may be less prominent than in Alzheimer’s disease.

5. DIFFERENTIAL DIAGNOSIS

Alzheimer’s disease, Parkinson’s disease dementia, Lewy body dementia, and frontotemporal dementia. Distinguishes by pattern of cognitive impairment, neuroimaging findings, and response to treatment.

5.1 Key Differentiators

VCID often shows stepwise decline, focal deficits, or mixed vascular-neurodegenerative features. Alzheimer’s disease typically presents with memory loss as the dominant feature.

5.2 Imaging Findings

MRI reveals vascular lesions (lacunes, microbleeds) vs. Alzheimer’s-associated hippocampal atrophy.

6. INVESTIGATIONS & DIAGNOSIS

MRI is essential for detecting small-vessel disease (lacunar infarcts, microbleeds, white matter hyperintensities). Cognitive screening tools (e.g., six-item screener) assess decline. CSF biomarkers may help differentiate from Alzheimer’s disease.

6.1 Diagnostic Algorithm

1. Clinical history of stroke or vascular risk factors. 2. MRI to identify vascular lesions. 3. Cognitive screening (e.g., MoCA, MMSE). 4. Exclude other dementias via neuroimaging and biomarkers.

6.2 MRI Findings

Lacunar infarcts (FLAIR hyperintensity), microbleeds (T2*-weighted hypointensity), and white matter hyperintensities (FLAIR hyperintensity) are key markers.

7. MANAGEMENT & TREATMENT

Lifestyle modifications (diet, exercise), blood pressure control (target SBP <120 mmHg), and management of vascular risk factors. No specific antidementia drugs, but cholinesterase inhibitors may be used in mixed dementia. Rehabilitation for functional impairment.

7.1 Pharmacologic Therapy

Cholinesterase inhibitors (donepezil, rivastigmine) may be used in mixed dementia. Antihypertensives (e.g., ACE inhibitors) for vascular risk reduction.

7.2 Non-Pharmacologic Interventions

Cognitive rehabilitation, physical exercise, and management of comorbidities (hypertension, diabetes).

8. PROGNOSIS & COMPLICATIONS

Poor prognosis with progressive cognitive decline. Complications include falls, functional disability, and increased mortality. Early intervention with blood pressure control may slow progression.

8.1 Prognostic Factors

Severity of vascular injury, presence of comorbid neurodegenerative disease, and response to blood pressure management.

8.2 Complications

Poststroke cognitive decline, gait disturbances, and increased risk of recurrent strokes.

9. SPECIAL CONSIDERATIONS

No specific population-based considerations mentioned. Management focuses on vascular risk factor control and multidisciplinary care.

9.1 Mixed Dementia

Common in elderly; management includes addressing both vascular and neurodegenerative components.

9.2 Research Applications

Diffusion tensor MRI and functional MRI may identify early vascular injury before clinical symptoms appear.

10. KEY POINTS & CLINICAL PEARLS

1. VCID encompasses all cerebrovascular contributions to dementia, including large strokes and small-vessel disease. 2. MRI is critical for diagnosis and monitoring. 3. SBP <120 mmHg reduces dementia risk by 15%. 4. Mixed vascular-neurodegenerative dementias are more common than single-etiology dementias. 5. Early intervention with vascular risk reduction may slow cognitive decline.